This combination of initial signs is termed a clinically isolated syndrome (CIS), although CIS does not always convert to MS. The risk factors for relapse (conversion to clinically definite MS ...

Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study ...

Tom Nolan reviews this week’s research There are so many studies published about vitamin D—about a dozen each day—it’s hard to keep up. One that stands out is a double-blind randomised controlled ...

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing ...

Learn more about whether Moderna, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Norges Bank acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional ...